Inventiva S.A (IVA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Inventiva S.A (IVA) has a cash flow conversion efficiency ratio of 1.796x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-51.24 Million ≈ $-59.90 Million USD) by net assets (€-28.52 Million ≈ $-33.35 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Inventiva S.A (IVA) market capitalisation for the company's overall valuation and market capitalisation.
Inventiva S.A - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Inventiva S.A's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Inventiva S.A Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Inventiva S.A ranked by their cash flow conversion efficiency. See IVA operating cash flow to total debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shenzhen Tellus Holding Co Ltd
SHE:000025
|
0.009x |
|
AB SKF (publ)
ST:SKF-A
|
0.034x |
|
Abacus Global Management, Inc.
NYSE:ABX
|
0.089x |
|
JM AB (publ)
ST:JM
|
-0.005x |
|
Compass Diversified Holdings
NYSE:CODI
|
0.049x |
|
Shandong Shanda Wit Science and Technology Co Ltd
SHE:000915
|
0.147x |
|
Zhejiang Qianjiang Motorcycle Co Ltd
SHE:000913
|
0.000x |
|
Allis Electric Co Ltd
TW:1514
|
-0.040x |
Annual Cash Flow Conversion Efficiency for Inventiva S.A (2013–2025)
The table below shows the annual cash flow conversion efficiency of Inventiva S.A from 2013 to 2025. View Inventiva S.A share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €-28.52 Million ≈ $-33.35 Million |
€-104.88 Million ≈ $-122.62 Million |
3.677x | +356.39% |
| 2024-12-31 | €-106.65 Million ≈ $-124.68 Million |
€-85.93 Million ≈ $-100.46 Million |
0.806x | -68.38% |
| 2023-12-31 | €-32.03 Million ≈ $-37.45 Million |
€-81.61 Million ≈ $-95.42 Million |
2.548x | +357.90% |
| 2022-12-31 | €45.48 Million ≈ $53.17 Million |
€-44.93 Million ≈ $-52.53 Million |
-0.988x | -84.33% |
| 2021-12-31 | €88.87 Million ≈ $103.89 Million |
€-47.63 Million ≈ $-55.68 Million |
-0.536x | -94.85% |
| 2020-12-31 | €111.21 Million ≈ $130.02 Million |
€-30.59 Million ≈ $-35.76 Million |
-0.275x | +59.92% |
| 2019-12-31 | €41.39 Million ≈ $48.39 Million |
€-28.40 Million ≈ $-33.21 Million |
-0.686x | -23.57% |
| 2018-12-31 | €61.60 Million ≈ $72.01 Million |
€-34.21 Million ≈ $-39.99 Million |
-0.555x | -109.07% |
| 2017-12-31 | €64.01 Million ≈ $74.83 Million |
€-17.00 Million ≈ $-19.88 Million |
-0.266x | +36.15% |
| 2016-12-31 | €35.72 Million ≈ $41.76 Million |
€-14.86 Million ≈ $-17.37 Million |
-0.416x | -27.24% |
| 2015-12-31 | €42.77 Million ≈ $50.00 Million |
€-13.98 Million ≈ $-16.35 Million |
-0.327x | -13.88% |
| 2014-12-31 | €51.51 Million ≈ $60.22 Million |
€-14.79 Million ≈ $-17.29 Million |
-0.287x | -5.83% |
| 2013-12-31 | €59.01 Million ≈ $68.99 Million |
€-16.01 Million ≈ $-18.72 Million |
-0.271x | -- |
About Inventiva S.A
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat … Read more